NOVARTIS VENTURE FUND
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment ... in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics & platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
NOVARTIS VENTURE FUND
Industry:
Finance Therapeutics Venture Capital
Founded:
1996-01-01
Status:
Active
Contact:
877 280 2296
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Universal Analytics DigiCert SSL GlobalSign Domain Verification Proofpoint Imperva Bot Detection And Mitigation
Similar Organizations
ABB Technology Ventures
ABB Technology Ventures (ATV) is the strategic venture capital unit of ABB (NYSE: ABB).
ALSA Ventures
ALSA Ventures invest in biotechnology companies passionate about bringing novel therapies to patients.
BB Biotech Ventures
BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices.
Civilization Ventures
Civilization Ventures is a venture capital firm focused on cutting edge innovations in exponential health tech and biology.
Claris Ventures
Claris Ventures is a venture capital firm focused on early-stage investments in high potential biopharma companies.
Digitalis Ventures
Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health.
EIR Ventures
EIR Ventures is a new Life Science Venture Group in the Nordics.
Forward Ventures
Forward Ventures ic a venture capital company that focuses in companies in the area of biological sciences.
Founders Fund
Founders Fund is a venture capital firm investing in companies building revolutionary technologies.
Hikma Ventures
Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
Kibo Ventures
Kibo Ventures is a venture capital fund investing in early-stage internet and mobile companies.
LocalGlobe
LocalGlobe is a venture capital firm that focuses on seed and impact investments.
Novalis LifeSciences
Novalis Lifesciences is a globally acting venture capital firm focused on breakthrough technologies in Life Science.
Roche Venture Fund
The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche.
Samsung Ventures
Samsung Ventures is a venture capital firm specializing in investments in start-up companies.
TA Ventures
TA Ventures is an international venture capital firm backing ambitious founders of technology companies across Europe and North America.
Union Square Ventures
Union Square Ventures is a venture capital firm focused on early-stage, growth-capital, late stage, and startup financing.
VentureFriends
VentureFriends is a venture capital fund that invests in tech-enabled companies.
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-02 | Epsilogen | Novartis Venture Fund investment in Series B - Epsilogen | 30.75 M GBP |
| 2022-02-15 | Splice Bio | Novartis Venture Fund investment in Series A - Splice Bio | 50 M EUR |
| 2022-01-20 | ImmPACT Bio | Novartis Venture Fund investment in Series B - ImmPACT Bio | 111 M USD |
| 2021-12-28 | IKAS Industrial Automation | Novartis Venture Fund investment in Series B - IKAS Industrial Automation | 100 M CNY |
| 2021-12-16 | Anaveon | Novartis Venture Fund investment in Series B - Anaveon | 110 M CHF |
| 2021-11-23 | LOQUS23 THERAPEUTICS | Novartis Venture Fund investment in Seed Round - LOQUS23 THERAPEUTICS | 7 M GBP |
| 2021-11-15 | Kedalion Therapeutics | Novartis Venture Fund investment in Series B - Kedalion Therapeutics | N/A |
| 2021-10-05 | Exo Therapeutics | Novartis Venture Fund investment in Series B - Exo Therapeutics | 78 M USD |
| 2021-09-29 | Expansion Therapeutics | Novartis Venture Fund investment in Series B - Expansion Therapeutics | 80 M USD |
| 2021-09-15 | Flywheel.io | Novartis Venture Fund investment in Series C - Flywheel.io | 22 M USD |
More informations about "Novartis Venture Fund" on Search Engine
About Us | Novartis Venture Fund
Our fund invests in a wide array of companies working in biotechnology and biopharmaceuticals at all stages of growth and development. We manage over USD 750 million in committed capital and more than 40 portfolio companies across North America and Europe. Meet the NVF team.See details»
Biopharma/Biotech Investment | Novartis Venture Fund
Currently managing approximately USD 750 million, our life science venture fund is strategically positioned to make impactful equity investments in pioneering biotechnology and biopharmaceutical companies. We actively seek out opportunities that demonstrate exceptional potential.See details»
Novartis Venture Fund Team - nvfund.com
Find out more about the people on our team. The Novartis Venture Fund Team is made up of people with proven expertise and talent in bringing exciting new drugs and treatments to patients all over the world. Drawing on successful backgrounds in medicine, science, legal, investment, and business development, the investment team has an undeterred ...See details»
Novartis Venture Fund - Crunchbase Investor Profile & Investments
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms. Basel, Basel-Stadt, Switzerland. 11-50. Corporate Venture Capital, Venture Capital. Early Stage Venture, Late Stage Venture, Post-Ipo, Secondary Market, Seed. www.nvfund.com.See details»
Novartis Venture Fund Investor Profile: Portfolio & Exits - PitchBook
Apr 1, 2024 Founded in 1996, Novartis Venture Fund is a corporate venture capital investment arm of Novartis based in Basel, Switzerland. The firm has a regional office in Cambridge, Massachusetts. The firm seeks to invest in the life sciences, oncology, biotechnology, and digital health sectors. Business Details. Website. www.nvfund.com. …See details»
Novartis Venture Fund - Investments, Portfolio & Company Exits
About. Novartis Venture Fund has made 256 investments. Their most recent investment was on Apr 11, 2024, when FundaMental Pharma raised. €2.7M. Novartis Venture Fund has made 39 diversity investments. Their most recent diversity investment was on Aug 18, 2021, when Immunitas Therapeutics raised. $58M.See details»
Novartis Venture Fund - Funding, Financials, Valuation & Investors
Novartis Venture Fund has raised a total of $720M across 3 funds, their latest being Novartis Option Fund (NOF). This fund was announced on Jan 1, 2009 and raised a total of $200MSee details»
Novartis Venture Fund: Profile, Investments & Returns | PitchBook
Sep 18, 2017 General Information. Description. Novartis Venture Fund was a venture capital fund managed by Novartis Venture Fund. The fund was located in Basel, Switzerland and invested in Europe, North America and Israel. The fund targeted healthcare, pharmaceuticals and biotechnology, life science and oncology sectors.See details»
Novartis Venture Fund (NVF) - life-sciences-europe.com
The Novartis Venture Funds, established in 1996 currently manage over $750 million in committed capital. NVF invests in companies which have the potential to change a core therapeutic field or explore new business areas that will be critical to patient care.See details»
Our pharma portfolio strategy | Novartis Venture Fund
The Novartis Venture Fund currently invests in over 40 life science companies across North America and Europe with approximately USD 750 million under management. Our investment strategy. We specialize in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies.See details»
Novartis Venture Funds - CB Insights
Mar 3, 2023 Novartis Venture Funds primarily focuses on the development of novel therapeutics and platforms. NVF looks for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program.See details»
The Novartis Venture Fund - A Model Corporate VC Innovation …
Nov 8, 2010 -Top Corporate VC. ~70% of Investment in the US (End of 2009) Around 150 Programs: A (Midsized) Pharma Company(End of 2009) 24%24% Haematology/Oncology ID NS 18% 12% 9% 8% 5% Inflammation Respiratory CV Varia. Two Choices for Capital. Novartis Venture Fund.See details»
Novartis Venture Fund - National Venture Capital Association
Dec 28, 2022 Novartis Venture Fund. nvcaprod. Published on December 28, 2022.See details»
Novartis Venture Fund Portfolio Companies - Crunchbase
Aug 15, 2007 Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms. This list of organizations invested in by Novartis Venture Fund provides data on their funding history, investment activities, and acquisition trends. Insights about top trending companies, startups, investments and M&A. Read More.See details»
Our Successes | Novartis Venture Fund
The Novartis Venture Fund invests in life science companies with products that answer unmet clinical needs, achieving successful exits including IPOs, mergers and acquisitions, and FDA drug approvals.See details»
p h a r m a c e u t i c a l s New frontiers in pharma R&D investment
Than 15 percent of its annual R&D budget—to its venture funds (Exhibit 4). These venture investments are made through three complementary vehicles—the original Novartis Venture Fund; the Novartis Option Fund, focused on securing options to specific programs; and a coinvestment fund with MPM Capital.See details»
Managing Director at Novartis Venture Fund - The Org
Dr. Aaron Nelson is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he was an investor at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine.See details»
Novartis Venture Fund | Golden
Novartis Venture Fund is a corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms. Founded 1996 in Basel-Stadt, Switzerland by Argeris Karabelas, it invests in early stage ventures, late stage venture, post-IPO, secondary markets, seed, series A, series B, series C, and post-IPO equity.See details»
Novartis Venture Fund - Contacts, Employees, Board Members, …
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.See details»
Mergers & Acquisitions | Novartis Venture Fund
Since its foundation in 1996, the Novartis Venture Fund has developed exit strategies that have helped guide over 30 of its portfolio companies to successfully complete transformational M&A transactions with a diverse group of large international pharmaceutical companies. Explore our M&A successes.See details»